Self Adjuvanting CTL-Based Influenza Vaccines for Human Use

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/400580

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

This project will generate novel vaccines that elicit cell-mediated immunity against influenza infection. The vaccines are totally synthetic and therefore not constrained by the limitations in manufacturing which currently confront egg-grown vaccines. These vaccines induce very strong immune responses because they target dendritic cells which are pivotal for induction of all immune responses. This targeting capability is due to a simple lipid molecule incorporated into the vaccine which is recognised by specific receptors on the surface of dendritic cells and also causes their maturation, a step which is essential for recognition by the immune system of potential pathogens. The technology to design and assemble these new vaccines is already.

Funded Activity Details

Start Date: 01-01-2006

End Date: 01-01-2007

Funding Scheme: NHMRC Strategic Awards

Funding Amount: $214,842.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Infectious Diseases

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

CD8+ T cell vaccines | Cell-mediated immunity | Epitope-based self adjuvanting vaccines | iNFLUENZA VACCINES

Related Links